Inspire Medical Systems (NYSE:INSP) Given New $85.00 Price Target at Piper Sandler

Inspire Medical Systems (NYSE:INSP) had its target price lowered by equities research analysts at Piper Sandler from $165.00 to $85.00 in a note issued to investors on Thursday,Benzinga reports. The firm currently has an “overweight” rating on the stock. Piper Sandler’s price target points to a potential upside of 24.10% from the company’s previous close.

Other equities research analysts have also recently issued reports about the company. Royal Bank Of Canada cut Inspire Medical Systems from an “outperform” rating to a “sector perform” rating and dropped their price objective for the company from $175.00 to $90.00 in a research note on Tuesday, January 27th. Robert W. Baird set a $74.00 target price on Inspire Medical Systems and gave the company a “neutral” rating in a report on Thursday. JPMorgan Chase & Co. lifted their target price on Inspire Medical Systems from $82.00 to $118.00 and gave the company a “neutral” rating in a research report on Tuesday, December 16th. Zacks Research raised shares of Inspire Medical Systems from a “strong sell” rating to a “hold” rating in a research report on Monday, October 27th. Finally, Truist Financial lowered shares of Inspire Medical Systems from a “buy” rating to a “hold” rating and set a $96.00 price objective for the company. in a research note on Thursday, January 22nd. Six analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $113.94.

Inspire Medical Systems Stock Performance

Inspire Medical Systems stock opened at $68.50 on Thursday. The company’s 50 day simple moving average is $96.03 and its 200-day simple moving average is $91.70. Inspire Medical Systems has a 1 year low of $64.46 and a 1 year high of $197.75. The company has a market capitalization of $1.99 billion, a price-to-earnings ratio of 46.60, a price-to-earnings-growth ratio of 6.87 and a beta of 0.74.

Inspire Medical Systems (NYSE:INSP) last posted its quarterly earnings data on Wednesday, February 11th. The company reported $1.65 earnings per share for the quarter, topping analysts’ consensus estimates of $0.69 by $0.96. The firm had revenue of $269.08 million during the quarter, compared to analysts’ expectations of $264.02 million. Inspire Medical Systems had a net margin of 5.05% and a return on equity of 9.41%. The firm’s quarterly revenue was up 12.2% on a year-over-year basis. During the same quarter last year, the company posted $1.15 EPS. Equities analysts expect that Inspire Medical Systems will post 2.16 earnings per share for the current year.

Insider Activity at Inspire Medical Systems

In other news, Director Shawn Mccormick sold 2,000 shares of the firm’s stock in a transaction on Friday, November 28th. The shares were sold at an average price of $127.48, for a total value of $254,960.00. Following the sale, the director directly owned 26,046 shares in the company, valued at approximately $3,320,344.08. This trade represents a 7.13% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 4.10% of the company’s stock.

Hedge Funds Weigh In On Inspire Medical Systems

A number of institutional investors and hedge funds have recently modified their holdings of INSP. Manning & Napier Advisors LLC acquired a new stake in Inspire Medical Systems in the third quarter valued at $32,000. CWM LLC boosted its position in shares of Inspire Medical Systems by 216.1% during the 4th quarter. CWM LLC now owns 354 shares of the company’s stock worth $33,000 after acquiring an additional 242 shares in the last quarter. Havemeyer Place LP acquired a new position in shares of Inspire Medical Systems during the 4th quarter worth about $39,000. V Square Quantitative Management LLC purchased a new position in shares of Inspire Medical Systems in the 4th quarter valued at about $40,000. Finally, Larson Financial Group LLC raised its position in shares of Inspire Medical Systems by 21,266.7% during the 3rd quarter. Larson Financial Group LLC now owns 641 shares of the company’s stock worth $48,000 after acquiring an additional 638 shares in the last quarter. Institutional investors and hedge funds own 94.91% of the company’s stock.

Trending Headlines about Inspire Medical Systems

Here are the key news stories impacting Inspire Medical Systems this week:

• Positive Sentiment: Q4 beat: EPS of $1.65 vs. Street ~$0.70 and revenue of $269.1M (+12% y/y), showing better-than-expected top- and bottom-line execution. Article Title
• Positive Sentiment: Strong full-year metrics and liquidity: 2025 revenue $912M (+14%), operating cash flow $117M, and $175M in share repurchases — supports cash generation and shareholder return capacity. Article Title
• Neutral Sentiment: Management commentary and detail available — full earnings-call transcript and slide deck provide color on Inspire V adoption, payer engagement and margin assumptions for 2026. Useful for modeling scenarios and hearing management’s mitigation plans. Article Title
• Negative Sentiment: Coding & reimbursement risk: Company said recent coding clarification points clinicians to CPT 64582 with a -52 modifier for Inspire V, which may lower physician reimbursement and slow procedure adoption; as a result management narrowed/revised 2026 revenue guidance to $950M–$1.0B (growth ~4%–10%), reflecting meaningful uncertainty. Article Title
• Negative Sentiment: Market reaction and positioning: Shares reportedly slid after the coding/guidance update (coverage noted a roughly 8% drop) and short interest rose materially in January to ~13.6% of float (up ~31%), increasing downside pressure and potential volatility. Article Title

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.